Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target Raised to $17.00
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) had its price target hoisted by HC Wainwright from $15.00 to $17.00 in a report released on Monday morning, MarketBeat.com reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also weighed in on TTPH. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating and raised their price objective for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. BMO Capital Markets reaffirmed an outperform rating and set a $13.00 price objective (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Needham & Company LLC reaffirmed a hold rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating and set a $6.25 price objective for the company in a report on Wednesday, August 9th. Finally, BidaskClub lowered shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $15.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at $6.30 on Monday. Tetraphase Pharmaceuticals has a fifty-two week low of $3.39 and a fifty-two week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.63). The company had revenue of $4.10 million during the quarter, compared to analyst estimates of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The company’s revenue was up 355.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.58) earnings per share. sell-side analysts anticipate that Tetraphase Pharmaceuticals will post -2.83 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/09/tetraphase-pharmaceuticals-inc-ttph-price-target-raised-to-17-00.html.
In related news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the sale, the insider now owns 17,500 shares of the company’s stock, valued at $105,000. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 33,405 shares of company stock valued at $199,691. 5.50% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the stock. California Public Employees Retirement System increased its holdings in shares of Tetraphase Pharmaceuticals by 2.0% in the second quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock valued at $1,727,000 after purchasing an additional 4,800 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Tetraphase Pharmaceuticals by 6.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock worth $1,184,000 after acquiring an additional 7,866 shares during the period. Vanguard Group Inc. grew its holdings in Tetraphase Pharmaceuticals by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after acquiring an additional 230,420 shares during the period. Bank of New York Mellon Corp grew its holdings in Tetraphase Pharmaceuticals by 3.4% during the 1st quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock worth $1,726,000 after acquiring an additional 6,114 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Tetraphase Pharmaceuticals by 17.0% during the 1st quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock worth $2,880,000 after acquiring an additional 45,554 shares during the period. 42.68% of the stock is owned by institutional investors and hedge funds.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.